Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-05-10-Speech-2-422-750"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2011-05-10"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20110510.60.2-422-750"2
lpv:hasSubsequent	lp_eu:2011-05-10-Speech-2-423-0002
lpv:speaker	lp:Marielle de Sarnez2
lpv:spokenAs	member; INTA (2009-07-16--2012-01-18)3 substitute; Delegation to the Euro-Latin American Parliamentary Assembly (2009-09-16--2014-06-30)3 vice-chair; ALDE (2009-07-14--2014-06-30)3 substitute; AFET (2009-07-16--2012-01-18)3 unknown; Mouvement Démocrate (2009-07-14--2014-06-30)3 member; Delegation to the ACP-EU Joint Parliamentary Assembly (2009-09-16--2014-06-30)3 substitute; Delegation for relations with the countries of the Andean Community (2009-09-16--2014-06-30)3
lpv:translated text	"In the absence of sufficient guarantees as to the independence of the experts recruited to perform scientific assessments on medicines for human use, we have voted to postpone granting the Executive Director of the European Medicines Agency discharge in respect of the implementation of the Agency’s budget for the financial year 2009. In particular, this issue of independence concerns the assessment of the appetite suppressant benfluorex, the active ingredient in the product Mediator, which may have suffered from conflicts of interest. It appears that this drug may have been responsible for the deaths of an estimated 500–2 000 people and caused severe heart damage in thousands of others. This case reveals a degree of failure of expert assessments and raises the question of the experts’ skill and independence in our risk society. We must therefore be seen to be extremely vigilant. This is why we refused to give our blanket approval."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph